Lyterian Therapeutics
Andrew Manford started their work experience as a Postdoc at UC Berkeley in March 2014. Andrew worked in this role until November 2022. In November 2022, Andrew joined Lyterian Therapeutics as a Senior Scientist, where they are currently employed.
Andrew Manford has a strong educational background in the field of biochemistry and molecular biology. From 2002 to 2006, they pursued their Bachelor of Science (BS) degree at the University of California, Davis. Following this, they enrolled at Cornell University, where they completed their Doctor of Philosophy (PhD) in Biochemistry, Molecular and Cell Biology between 2007 and 2014.
This person is not in any offices
Lyterian Therapeutics
1 followers
Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
Employees
1-10